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Abstract
Background: The prevalences and risk factors of microalbuminuria are not full described among black African
diabetic patients. This study aimed at determining the prevalence of microalbuminuria among African diabetes
patients in Dar es Salaam, Tanzania, and relate to socio-demographic features as well as clinical parameters.
Methods: Cross sectional study on 91 Type 1 and 153 Type 2 diabetic patients. Two overnight urine samples per
patient were analysed. Albumin concentration was measured by an automated immunoturbidity assay. Average
albumin excretion rate (AER) was used and were categorised as normalbuminuria (AER < 20 ug/min),
microalbuminuria (AER 20–200 ug/min), and macroalbuminuria (AER > 200 ug/min). Information obtained also
included age, diabetes duration, sex, body mass index, blood pressure, serum total cholesterol, high-density and
low-density lipoprotein cholesterol, triglycerides, serum creatinine, and glycated hemoglobin A1c.
Results: Overall prevalence of microalbuminuria was 10.7% and macroalbuminuria 4.9%. In Type 1 patients
microalbuminuria was 12% and macroalbuminuria 1%. Among Type 2 patients, 9.8% had microalbuminuria, and
7.2% had macroalbuminuria. Type 2 patients with abnormal albumin excretion rate had significantly longer diabetes
duration 7.5 (0.2–24 yrs) than those with normal albumin excretion rate 3 (0–25 yrs), p < 0.001. Systolic and
diastolic blood pressure among Type 2 patients with abnormal albumin excretion rate were significantly higher than
in those with normal albumin excretion rate, (p < 0.001).
No significant differences in body mass index, glycaemic control, and cholesterol levels was found among patients
with normal compared with those with elevated albumin excretion rate either in Type 1 or Type 2 patients.
A stepwise multiple linear regression analysis among Type 2 patients, revealed AER (natural log AER) as the
dependent variable to be predicted by [odds ratio (95% confidence interval)] diabetes duration 0.090 (0.049, 0.131),
p < 0.0001, systolic blood pressure 0.012 (0.003–0.021), p < 0.010 and serum creatinine 0.021 (0.012, 0.030).
Conclusion: The prevalence of micro and macroalbuminuria is higher among African Type 1 patients with
relatively short diabetes duration compared with prevalences among Caucasians. In Type 2 patients, the prevalence
is in accordance with findings in Caucasians. The present study detects, however, a much lower prevalence than
previously demonstrated in studies from sub-Saharan Africa. Abnormal AER was significantly related to diabetes
duration and systolic blood pressure.
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Diabetic nephropathy accounts for a significant reduction
in life expectancy of diabetic patients. It is the leading
cause of end-stage renal disease in the western world [1,2].
In Caucasians, the cumulative incidence of diabetic neph-
ropathy in Type 1 and Type 2 diabetic patients has been
estimated to range from 20% to 27% after a diabetes dura-
tion of 20 years [3,4].
Extensive studies in the Western world have demonstrated
that diabetic patients with microalbuminuria have
increased risk of progression to overt proteinuria, and
after some time, renal failure. The progression of diabetic
nephropathy from the appearance of clinical proteinuria
to end stage renal failure is usually irreversible. Without
any intervention, approximately 80% Type 1 patients with
persistent microalbuminuria develop overt nephropathy
after 10–15 years. Eventually 50% of these develop end
stage renal failure within 10 years and 75% by 20 years
[5]. In Type 2 diabetic patients, 20–40% with microalbu-
minuria progress to overt nephropathy and 20 years later,
approximately 20% develop end stage renal failure [6].
There is a racial difference in the prevalence of diabetic
nephropathy and end stage renal failure. African Ameri-
can patients for instance have been reported to suffer
greater diabetic nephropathy and kidney damage than
Caucasian Americans [7,8].
Information on nephropathy in African diabetic popula-
tions is scarce. Available data between 1971 and 2002
shows the prevalence of microalbuminuria in Africa to
vary between 26% and 57% in diabetic patients, with var-
iable duration of the disease [9-12], [Table 1]
Early medical treatment and lifestyle adjustments have
been shown to halt the progression from micro- to mac-
roalbuminuria and eventually end stage renal failure
[13,14]. Therefore, detection of microalbuminuria as
early as possible in the course of the disease is very impor-
tant. In the developing countries, this is even more so
because of the economical constraints, kidney replace-
ment therapy is seldom an option.
The aim of this study was to determine the prevalence of
microalbuminuria and diabetic nephropathy among Type
1 and Type 2 African diabetic patients in Dar es Salaam.
We also wanted to assess the interrelation of microalbu-
minuria with basic patient socio-demographic features as
well as clinical and biochemical parameters.
Methods
Patients attending the Muhimbili outpatient diabetic
clinic for their regular visits and who accepted to partici-
pate in the study were included. The study was done from
July 2003 to March 2004. Informed consent verbally and
in writing was obtained from all patients and were inter-
viewed using a standardized questionnaire. The history
including date of diabetes diagnosis, family history of dia-
betes, history of cigarette smoking, age, gender and date of
presentation were obtained.
Patients were enrolled in two steps. In step 1, 204 consec-
utive patients were included. Secondly, to enlarge the
group of Type 1 patients, 68 consecutive patients aged 30
years or younger and on insulin therapy were enrolled.
Patients were classified into Type 1 and Type 2 according
to the WHO clinical stage criteria [15] using information
from each patient's diabetes sheet and data collected at
enrolment. Patients not fitting into the clinical features of
either type were classified as undetermined.
Clinical assessment
Weight was measured without shoes or heavy clothing
with a SECCA® scale. It was recorded to the nearest 0.5 kil-
ogram. Height was determined to the nearest 0.5 cm with
a rigid measure against a vertical wall.
Blood pressure was measured with a suitable mercury
sphygmomanometer. After a 10 minutes rest with the
Table 1: Prevalences of microalbuminuria in people with diabetes among Africans
Study Type of 
diabetes
N Age (years) Duration 
(years)
urine sample AER criteria albumin assay Prevalences
Erasmus, RT 
1992 Nigeria
Type 2 113 51.1 yrs 0.2–25 24 hr urine one 
sample
Micro = ≥30 mg/24 hr Immunodiffusion microalb 57%
52%-dur<5 yrs
Rahlenbeck, SI 
1997 Ethiopia
IDDM- 71 32.6 ± 9.5
30.6 ± 8.9
6.0 ± 4.9
11.4 ± 6.7
Spot morning 
(3 consecutive visits)
Urinary alb conc. micro = 30–299 mg/L
macro = >300 mg/L
MICRAL microalb-32%
macrolb-15%
NIDDM- 99 55.4 ± 13
59.9 ± 8
5.3 ± 3.9
10.3 ± 5.5
microalb-37%
macroalb-20%
Sobngwi, E 1999 
Cameroon
Type 1
Type 2
9
55
19–70 yrs 1–23 yrs Overnight urine UAE rate micro = 30 mg/24 hr MICRAL microalb 53,1%
Wanjohi, FW 
2002 Kenya
Type 2
New
100 53.7 ± 9.3 10.3 ± 7.5 
(months)
Spot morning-one 
sample
Urinary alb conc. Cut of limits not 
defined
MICRAL microalb-26%
macroal b-1pt
Current Study 
2006 Tanzania
Type 1
Type 2
91
153
21 (4–44.8)
53 (24–85)
3(0–17)
4(0–25)
Timed overnight 2 
samples
AER Immunoturbidimetry T1micro-12.1%
T1macro-1.1%
T2micro-9.8%
T2macro-7.2%Page 2 of 8
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ured two times at 5 minutes interval. The 1st and the 5th
Korotokoff's sound were used to determine the systolic
(SBP) and diastolic blood pressure (DBP) measurements
respectively. The second blood pressure measurement was
used as the blood pressure for the individual. Hyperten-
sion was defined as SBP ≥140 and/or DBP of ≥90 mmHg
or use of hypertensive medication [16].
Blood sample collection and storage
A morning sample of 6–9 mls of venous blood was drawn
from each subject and centrifuged within 2 hours of col-
lection. The sera and urine samples were frozen at -80°C
and transported to Bergen using a dry ice-filled container.
Capillary blood glucose was measured using a HemoCue
AB glucose analyzer (Angelholm, Sweden). HbA1c was
measured immunochemically at the clinic using DCA
2000®+ (Bayer Corporation) [17]. The instrument is
standardized against the DCCT method [18]. Quality was
controlled using standard solutions.
Biochemical assays
Assessment of serum potassium, sodium, serum choles-
terol, high-density lipoproteins, and low-density lipopro-
tein, serum triglycerides, serum creatinine were done at
the Haukeland University hospital, Norway. Biochemical
tests were analyzed on a BM/Hitachi 917 Auto Analyzer.
(Boehringer Diagnostics, Mannheim) using kits supplied
by Boehringer Mannheim (Mannheim, Germany). Serum
and urine creatinine measured by modified kinetic Jaffé
reaction, serum cholesterol by Cholesterol Oxidase p-ami-
nophenazone (CHOD-PAP) and serum triglycerides by
Glycerol phosphate oxidase p-aminophenazone (GPO-
PAP) methods.
Urine collection
Two overnight urine specimens were collected on consec-
utive nights. All patients received clear oral and written
instruction on how to collect a timed overnight urine sam-
ple in a 2-liter plastic container with no preservatives.
Patients were instructed to empty the bladder and discard
the urine just before going to bed and to note the time. All
the urine collected after going to bed (sleeping time) and
first morning urine sample on waking up was collected
into the container and the time of the first morning sam-
ple recorded. Sample were delivered to the clinic the same
morning. Patients who were unable to comply with the
instructions or lived far from the hospital were admitted
and samples collected in the hospital. Collected urine
were measured and screened for signs of infection using a
dipstick (Multistix® 10SG reagent strips, Bayer Diagnos-
tics, UK) and microscopically. Samples found to be
infected were discarded; the patient treated accordingly
and after a week of cure allowed to re-submit another
sample. Samples were then frozen at -80°C until analysis
for albuminuria and urine creatinine in Norway.
Assessment of urinary albumin excretion
Urine albumin concentrations were determined using an
automated immunoturbidity method, (anti-human
serum albumin obtained from Dako, Oslo) with sensitiv-
ity of 2.3 mg/L and inter- and intra assay coefficients of
variation of 4.4% and 4.3% respectively (Dade Behring
Marburg Gmbh.USA). We used the average of the two
readings to determine the final urinary excretion rate
(AER). AER was then categorized as normoalbuminuria
(AER of < 20 μg/min), microalbuminuria (20–200 μg/
min) and macroalbuminuria (> 200 μg/min). Albumin to
creatinine ratio (ACR) was calculated and values ≥ 2.5 mg/
mmol for men, ≥3.5 mg/mmol for women defined as
microalbuminuria. Macroalbuminuria was defined as
ACR ≥30 mg/mmol for men and women.
Renal function
Creatinine clearance calculations using the Cockcroft
Gault Formula were used as a correlate of eGFR [19]. Find-
ings were classified according to stages of renal dysfunc-
tion as proposed by the National Kidney Foundation [20].
Ethics
The study was done in accordance with the amended
2000 Helsinki declaration. The Scientific and Publication
committee at the Muhimbili University College of Health
Sciences (MUCHS) and the Norwegian Regional Medical
Research Ethics Committees of Western Norway approved
the study protocol.
Statistical analysis
Distribution within groups was tested for skewness and
statistically significant differences of standard deviations.
Parametric and nonparametric tests were then used as
appropriate. Differences between proportions were
assessed by Fisher's Exact test or Chi-square test. Multiple
linear regression was performed with ln AER as the
dependent variable. Data were analyzed using SPSS ver-
sion 12 for Windows and GraphPad INSTAT-version 3.00
supplied by the GraphPad Software, Inc San Diego, USA.
P < 0.05 was considered statistically significant.
Results
Socio-demographic characteristics of the study population
Two hundred seventy one patients were consecutively
enrolled, 13 excluded because of incomplete data. Among
the remaining 258 patients (54.3% females), 198 were
enrolled in step one, 31 (15.6%) classified as Type 1, 153
(77.3%) as Type 2 and 14 (7.1%) as undetermined. Step
two recruited 60 Type 1 patients making 91 Type 1
patients. Only data of Type 1 and Type 2 patients were
analyzed further.Page 3 of 8
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patients (median age 21 vs 53 years, p < 0.001), had
shorter known duration with diabetes (3 vs 4 years, p <
0.05) and had poorer glycaemic control (median HbA1c
13.9% vs 9.9%, p < 0.001) than Type 2 patients. The
median SBP, DBP, serum creatinine and mean BMI levels
for Type 1 patients were significantly lower than those of
Type 2 patients (p < 0.001), [Table 2].
Albuminuria
Prevalence among Type 1 patients recruited in phase 1
was 5(16.7%) microalbuminuria, 0% macroalbuminuria
and for Type 1 patients recruited in phase 2, 6(9.8%)
microalbuminuria and 1(1.6%) macroalbuminuria, mak-
ing a combined prevalence of 12.1% microalbuminuria
and 1.1% of macroalbuminuria i.e. 12 (13.2%) had
abnormal AER. The corresponding prevalences for Type 2
patients were 26 (17%) for abnormal AER, 9.8% micro-
albuminuria and 7.2% macroalbuminuria.
A significant number of Type 2 patients 33 (22%) as com-
pared with 4 (4.6%) of Type 1 patients had reduced
glomerular filtration rate (GFR < 60 ml/min), (p < 0.001).
No patient was found to have end stage renal failure (GFR
< 15 mls/min).
Albuminuria and the associated risk factors
The median diabetes duration, SBP, DBP and proportion
of patients on anti-hypertensive drugs among Type 2
patients with abnormal AER was significantly higher than
for those patients with normal AER were (p < 0.001),
[Table 3].
The differences in age at inclusion, diabetes duration, SBP,
DBP, HbA1c, BMI, and creatinine clearance distribution
between patients with normalbuminuria and abnormal
AER levels were not statistically significant in Type 1
patients.
Of the 45 Type 2 patients using anti-hypertensive medica-
tion, 13 were using ACE-Inhibitors, 12 b-blockers, 7 cal-
cium channel blockers, 5 thiazides and 8 other drugs.
Type 2 patients with known diabetes duration of more
than 5 years had significantly larger proportion of patients
with abnormal AER levels (p < 0.05), higher DBP (p <
0.05), and poorer glycaemic control (p < 0.001) than
those patients with diabetes duration of 5 years or less. No
significant differences were noted in all the variables in
both duration ranges among Type 1 patients [Table 4].
Only six subjects (2.4%) were current smokers, 11.5%
had stopped smoking and 86.1% had never smoked. All
patients who were current smokers had normal albumin
excretion rates and only three of those who had stopped
smoking had abnormal AER.
Regression analysis
Linear regression analysis was performed with log(n) AER
as the dependent variable and diabetes duration, age at
inclusion, gender, BMI, HbA1c, SBP and DBP, serum cre-
atinine and cholesterol as covarites. Among Type 1 dia-
betic patients a simple linear regression analysis
demonstrated a significant association between diabetes
duration (p = 0.045). Among Type 2 patients, a simple lin-
ear regression analysis revealed diabetes duration (p <
0.001), SBP (p < 0.001), DBP (p = 0.007) and serum cre-
atinine (p < 0.001) to be correlated with log AER [Table
5].
A backward stepwise multiple linear regression analysis
by elimination procedure was used to identify factors that
might independently be associated with development of
albuminuria. Diabetes duration (p < 0.001) was picked as
the strong predictor for the development of AER and SBP
(p = 0.010) and serum creatinine (p = 0.016) for Type 2
diabetes but no variable for Type 1 diabetes was picked on
multiple regression analysis.
Table 2: Sociodemographic characteristics and basic data of Type 1 and Type 2 diabetic patients
Variables Type 1 diabetes N = 91 Type 2 diabetes N = 153
Male N (%) ‡‡ 45(47.4) 68 (44.2)ns
Age at inclusion (yrs) ‡ 21(4–44.8) 53 (23.5–85) ***
Diabetes duration (yrs) ‡ 3 (0–17) 4 (0–25)*
BMI (kg/m2) (mean ± SD) # 19.3 ± 3.8 27.8 ± 4.8***
SBP (mmHg)‡ 108 (72–140) 134 (90–210) ****
DBP (mmHg)‡ 74 (50–110) 84 (52–136) ****
Serum Creatinine (umol/L) ‡ 47 (14–124) 71 (6–234) ***
HbA1c (%) ‡ 13.9 (6.3–>14) 9.9(4.4–>14) ***
Data expressed as median (min-max) unless stated otherwise.
P values – * p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001
‡‡ Fisher's Exact test, ‡ Mann-Whitney test, #Unpaired t-testPage 4 of 8
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AER as the gold standard measurement and ACR, both
using average albumin levels detected on two overnight
urine samples using the RIA were made. The calculated
ACR showed a sensitivity of 81.6%, specificity of 99%
with a kappa coefficiency of agreement of 0.85, (95%CI
0.76, 0.95).
Discussion
This cross sectional study reveals a prevalence of micro-
albuminuria and its determinants in a selected population
from a diabetic clinic in Dar es Salaam, Tanzania. Preva-
lence for microalbuminuria (12.1%) among Type 1
patients in this study who had median diabetes duration
of 3.0 years was relatively high when compared with prev-
alences found among Type 1 Caucasians diabetic patients
with similar diabetes duration. In a longitudinal study, a
cumulative incidence of about 4% was found in 148 Type
1 diabetic patients after diabetes duration of three years
[21]. Other studies in Caucasians have reported preva-
lences of microalbuminuria in Type 1 patients from 7–
22% [22-24] however, in these studies disease duration
was much longer than in the present study. Among the
Type 2 patients in our study microalbuminuria was 9.8%,
and median diabetes duration 4 (0–25) years. This is com-
parable with findings in Caucasian Type 2 patients (8–
32%) [22,23,25-27].
This study is one of relatively few from sub-Saharan Africa
dealing with microalbuminuria. A Medline search on
microalbuminuria in diabetic patients revealed four com-
parable studies from sub-Saharan Africa [Table 1] which
display relatively high prevalences compared with our
findings. Screening for bacteriuria was done in these stud-
ies too. They used mainly the "MICRAL test" for urinary
albumin assessment. The MICRAL test is less sensitive
Table 4: Abnormal albuminuria (AER), age at inclusion, metabolic and blood pressure control and serum creatinine levels in relation 
to duration below and above 5 years among Type 1 and Type 2 diabetes.
Type 1 diabetes N = 91 Type 2 diabetes N = 153
Duration ≤5 yrs n = 73 Duration >5 yrs n = 18 Duration ≤5 yrs n = 91 Duration >5 yrs n = 62
Abnormal AER N (%)‡‡ 8 (10.9) 4(22.2) 9 (9.9) 17 (27.4)**
Microalbuminuria N (%) 7(9.6) 4(22.2) 8(8.8) 7(11.3)
Age at inclusion (yrs) ‡ 20.0 (4–44.8) 24.3(13.6–43) 51.5(23.5–80) 53.8(35.3–85)
Diabetes duration (yrs) ‡ 2 (0.0–5.0) 8.7(5.5–17)*** 2.0 (0.0–5.0) 9.0 (5.5–25.0)***
BMI kg/m2 (mean ± SD) # 19.3 ± 3.9 19.0 ± 3.3 28.4 ± 5.1 26.8 ± 4.1*
SBP mmHg ‡ 102 (72–140) 110 (90–140) 134(90–210) 140 (90–200)
DBP mmHg ‡ 70 (50–110) 77 (60–98) 81(52–106) 88 (60–136)*
Creatinine clearance (mls/min) ‡ 128 (46–481.8) 137.2 (96–161) 105(40–273.4) 106.4 (40.2–190.6)
Hba1c (%) ‡ 14 (7.4–>14) 12.7 (6.3–>14) 8.4 (4.4–>14) 10.8 (5.8–>14)***
Data expressed as median (min-max) unless stated otherwise
Tests – ‡‡Fischer's exact test#, ‡Mann Whitney test, # Unpaired t test
P value – *p < 0.05, **p < 0.01, ***p < 0.001
Table 3: Albuminuria in relation to age, sociodemographic, blood pressure and biochemical data among Type 1 and Type 2 patients
Type 1 diabetes N = (91) Type 2 diabetes N = (153)
NORMAL (N = 79) 
(AER ≤20 ug/min)
ABNORMAL (N = 12) 
(AER > 20 ug/min)
NORMAL (N = 127) 
(AER ≤20 ug/min)
ABNORMAL (N = 26) 
(AER > 20 ug/min)
Age at inclusion (yrs) ‡ 20.0 (4–44.8) 21.5 (11–38) 51.6 (23.5–85) 54(36.6–80)
Duration of diabetes (yrs) ‡ 3.0 (0–17) 4.2 (0–9) 3 (0–25) 7.5(o.2–24)***
BMI (kg/m2) (mean ± SD) # 19.3 ± 3.7 18.8 ± 4.4 27.9 ± 5 27 ± 4.7
SBP mmHg ‡ 109 (72–140) 108 (90–140) 130(90–210) 160 (110–200)***
DBP mmHg ‡ 72 (50–110) 80 (54–100) 82(52–120) 92 (70–136)***
AER (ug/min) ‡ 4.9 (0.65–19.9) 51 (22.7–290.2)*** 4.67 (1.29–18.92) 164.6 (22.1–2000)***
Creatinine clearance (mls/min) ‡ 129(46–481) 132(96.4–191) 107(40–273) 86.6(40–178.5)
HbA1c (%) ‡ 13.5(6.3–>14) 14(8.9–>14) 9.6(4.4–>14) 10.1(5.4–>14)
Proportion anti HT medication N(%)‡‡ 0 0 31(24) 15(58)**
Proportion with Hypertension N(%)‡‡ 7(9.7) 2 (18.2) 59(47.6) 21(80.8)**
Data expressed as median (min-max) unless stated otherwise.
‡ Mann Whitney test, # unpaired t test, ‡‡ Fischer's exact test
p value – *p < 0.05, **p < 0.01, ***p < 0.001Page 5 of 8
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study. The way of assessing albuminuria in this study
should not have caused lower prevalence of microalbu-
minuria but rather the opposite. Some studies have
shown decay in albumin concentration when urine sam-
ples were kept frozen at -20°C, but not with storage tem-
perature of -80°C as was applied in this study [28-30].
Even if freezing and thawing should have caused an albu-
min decay in our urine samples as well, this reduction
could hardly account for the big difference in albumin
excretion rates demonstrated between the present study
and the former studies from sub-Saharan Africa. Differ-
ences in design, setting, methods for collection of urine
and assessment of microalbuminuria, and patient popula-
tions may contribute to the differences found between
these African studies.
From table 1, one might get the impression of a decreasing
trend in the prevalence of microalbuminuria in Africa.
Decreasing prevalences of microalbuminuria and microv-
ascular complications have been reported from western
countries, which is attributed to improvement in meta-
bolic control, better treatment of hypertension, the use of
angiotensin converting enzyme inhibitors and angi-
otensin receptor blockers [31,32]. Even though tempting,
it is not appropriate to draw any firm conclusion, from the
studies listed in table 1, as to whether prevalence of micro-
albuminuria really is on a decrease in sub-Saharan Africa.
This is especially so since the use of angiotensin receptor
blockers and converting enzyme inhibitors is limited.
It is uncommon in Caucasian Type 1 patients to diagnose
microalbuminuria during the first five year [33,34]. In the
study by Marshall et al, only one patient with Type 1 dia-
betes of less than 5 years duration had an AER in the
microalbuminuria range [23]. Among Type 2 Caucasian
patients, the association of diabetes duration and micro-
albuminuria is equivocal [35,36]. In the current study,
patients with abnormal AER had longer known diabetes
duration than those with normal AER (4.2 versus 3 years),
for Type 1 and (7.5 versus 3 years, p < 0.001) for Type 2.
On regression analysis, known diabetes duration was
identified as a strong predictor for development of abnor-
mal albuminuria in Type 2 patients.
Poor glycaemic control is well defined contributor to the
development and progression of microalbuminuria
among Type 2 patients [35-38], as well as Type 1 patients
[22,39,40]. In contrast, most of the available studies from
sub-Saharan African including the present study fail to
demonstrate any significant relationship between the
level of glycaemic control and microalbuminuria. Gold-
schmid et al demonstrated a high prevalence of micro-
albuminuria and nephropathy among African-American
diabetic patients, they also showed that metabolic control
was not associated with the disease [7].
Elevated blood pressure is documented as the most signif-
icant contributing factor in the pathogenesis and the pro-
gression of abnormal AER and eventually development of
diabetic nephropathy in both Type 1 and Type 2 diabetic
patients [41-43]. In the present study, the median SBP and
DBP were lower among Type 1 than among Type 2
patients. When SBP and DBP of Type 1 patients with nor-
mal AER were compared with those with abnormal AER
there was no significant differences. In contrast however,
Type 2 patients with abnormal AER had statistically signif-
icant higher SBP and DBP than those with normal AER, (p
< 0.0001).
The number of Type 1 diabetic patients in this study was
limited and few had microalbuminuria. These limitations
probably account for the lack of statistical correlation to
the commonly acknowledged risk factors for microalbu-
minuria. Other limitations of the current study include
those inherent to patient reliability or compliance in com-
Table 5: Linear regression analysis of albuminuria (ln AER) with respect to potential covariates
Type 2 diabetes
Univariate analysis Adjusted analysis*
Covariates β 95% CI p-value β 95% CI p-value
Diabetes duration (yrs) 0.117 0.076, 0.159 0.000 0.090 0.049, 0.131 0.000
Age at inclusion (yrs) 0.003 -0.019, 0.025 ns
Gender-Male -0.283 -0.777, 0.211 ns
BMI (kg/m2) -0.043 -0.095, 0.010 ns
HbA1c % 0.065 0.035, 0.164 ns
SBP (mmHg) 0.019 0.010, 0–029 0.000 0.012 0.003, 0–021 0.010
DBP (mmHg) 0.023 0.006, 0.039 ns
S. creatinine (mmol/l) 0.021 0.012, 0.030 0.000 0.011 0.002, 0.020 0.016
S. cholesterol (mmol/l) 0.048 -0.149, 0.245 ns
* Results from forward/backwards stepwise selection Predictors in the model, diabetes duration, SBP, age, serum creatininePage 6 of 8
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urine collections. Incomplete urine collection will have an
effect of lowering the calculated AER and eventually
underestimating the actual prevalence of microalbuminu-
ria. This is however not supported by the calculated ACR
from the same sample that showed an agreement between
ACR and AER, the kappa coefficiency was 0.85, 95%CI of
(0.76, 0.95) which is considered to be a very good level of
agreement.
Conclusion
The occurrences of microalbuminuria detected in this
study are much lower than previously reported in studies
from sub-Saharan Africa and similar to what have been
found in Caucasian diabetic patients. In Type 2 diabetic
patients the duration of diabetes was the strongest predic-
tor; SBP and serum creatinine as well predicted increased
albumin excretion rate.
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